Cargando…

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies

BACKGROUND: The effects of filgotinib on patient-reported outcomes (PROs) from 3 trials in patients with active rheumatoid arthritis were investigated. METHODS: Methotrexate (MTX)-naïve patients received filgotinib 200 or 100 mg plus MTX (FIL200+MTX, FIL100+MTX), filgotinib 200 mg monotherapy (FIL20...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bingham, Clifton O., Walker, David, Nash, Peter, Lee, Susan J., Ye, Lei, Hu, Hao, Khalid, Javaria Mona, Combe, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722138/ https://www.ncbi.nlm.nih.gov/pubmed/34980223 http://dx.doi.org/10.1186/s13075-021-02677-7

Ejemplares similares

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
por: Aletaha, Daniel, et al.
Publicado: (2021)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
por: Tanaka, Yoshiya, et al.
Publicado: (2022)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
por: Balsa, Alejandro, et al.
Publicado: (2023)

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
por: Combe, Bernard G., et al.
Publicado: (2022)

The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
por: Bartlett, Susan J., et al.
Publicado: (2022)

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
por: Combe, Bernard G., et al.
Publicado: (2023)

Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials
por: Sholter, Dalton, et al.
Publicado: (2022)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2022)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2020)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
por: Genovese, Mark, et al.
Publicado: (2018)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies
por: Meng, Amy, et al.
Publicado: (2022)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials
por: Conaghan, Philip G, et al.
Publicado: (2023)

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials
por: Tesser, John, et al.
Publicado: (2023)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
por: Chandran, Vinod, et al.
Publicado: (2023)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
por: Pope, Janet E., et al.
Publicado: (2021)

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis
por: Soubrier, Martin, et al.
Publicado: (2016)

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
por: Tarrant, Jacqueline M., et al.
Publicado: (2020)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
por: Benucci, Maurizio, et al.
Publicado: (2023)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
por: Dougados, Maxime, et al.
Publicado: (2022)

Enhanced reactivity to pain in patients with rheumatoid arthritis
por: Edwards, Robert R, et al.
Publicado: (2009)

Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data
por: Shimizu, Hirohito, et al.
Publicado: (2020)

Filgotinib: A Clinical Pharmacology Review
por: Namour, Florence, et al.
Publicado: (2022)

Treatment goals for rheumatoid arthritis: patient engagement and goal collection
por: Predmore, Zachary, et al.
Publicado: (2023)

Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort
por: Mouterde, Gaël, et al.
Publicado: (2019)

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
por: Strand, Vibeke, et al.
Publicado: (2018)

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
por: Fleischmann, Roy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_22o0um1h40vac8jehn8op40rhj